Application of bifidobacterium animalis in improving tumor immunotherapy response

A technology for animal bifidobacterium and tumor treatment, applied in the field of biomedicine, can solve the problems of early termination of treatment, side effects, high price, etc., and achieve the effects of improving immunotherapy response, prolonging survival time, and simple treatment methods

Active Publication Date: 2021-04-09
SHENZHEN JUNTUO BIOTECHNOLOGY CO LTD
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, this type of treatment also has the following problems: slow onset, with a median onset time of 12 weeks, which may delay the patient's treatment time; some patients have poor treatment effect; cause side effects in patients, such as colitis, diarrhea, Immune-related adverse events (irAEs) such as dermatitis, hepatitis, and endocrine diseases may lead to early termination of treatment; and the price is too high for ordinary patients to afford

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bifidobacterium animalis in improving tumor immunotherapy response
  • Application of bifidobacterium animalis in improving tumor immunotherapy response
  • Application of bifidobacterium animalis in improving tumor immunotherapy response

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0107] Example 1: Bifidobacterium animalis subsp.Lactis alone or in combination with PD-1 immunosuppressant for the treatment of gastrointestinal tumors

[0108] 1.1 Materials, instruments and sources

[0109] Test drug:

[0110] Bifidobacterium animalis NexStrain 02 (deposit number: CGMCC No.20455)

[0111] Packing: 20g / pack x 1 pack, 1x 10 11 CFU / g

[0112] Storage temperature: 4°C

[0113] Isotype Control Antibody Rat IgG2a

[0114] Supplier: Sino-US Crown Biotechnology Co., Ltd.

[0115] Item No.: CVP039

[0116] Storage temperature: 4°C

[0117] aPD-1 antibody (RMP1-14)

[0118] Supplier: Sino-US Crown Biotechnology Co., Ltd.

[0119] Item No.: CVP033

[0120] Storage temperature: 4°C

[0121] Antibodies for Flow Cytometry (Table 1)

[0122] Table 1. Antibody information used in flow cytometry analysis

[0123]

[0124] Reagent:

[0125] Normal saline; supplier: Anhui Double Crane Pharmaceutical Co., Ltd.; batch number: 171005

[0126] RMPI1640; Supplier...

Embodiment 2

[0179] Embodiment 2: flow analysis (FACS)

[0180] On the 16th day after administration (24th day after cell inoculation), 5 tumors in each group were taken for FACS. The harvested tumor samples were digested into a single cell suspension, then added with BFA (bovine calf serum) for blocking, cultured for 4 hours and then harvested for staining. The data obtained after flow cytometry was applied to the computer was analyzed by Kaluza software (Table 6, Figure 4-7 ), all tests were two-tailed, and a p-value less than 0.05 was considered statistically significant.

[0181] Table 6. Results of flow cytometry analysis

[0182]

[0183] Note: P values ​​less than 0.05 are marked with a gray background

[0184]It can be seen from the above that the NexStrain 02 combined treatment group has significant differences compared with the control group in the following indicators: CD4+CD62L-CD44+, CD8+IFN-gamma+, CD4+TNF-alpha+ and Cr-1+CD86+. And the NexStrain 02+aPD- treatment gro...

Embodiment 3

[0185] Example 3: Bifidobacterium animalis subsp.Lactis administered simultaneously or in advance, alone or in combination with PD-1 immunosuppressant, for the treatment of gastrointestinal tumors

[0186] 3.1 Materials, instruments and sources

[0187] Experimental animals: BALB / c mice, female, 7-8 weeks old (the age of mice at the time of tumor cell inoculation), weighing 16.5-22.3 g, 84 mice. Purchased from Shanghai Lingchang Biotechnology Co., Ltd., animal certificate number: 20180003007017. Breeding environment: SPF grade.

[0188] The environmental conditions of the experimental animal breeding room: the experimental animals are all kept in an independent ventilation box with constant temperature and humidity, the temperature of the breeding room is 21-25°C, the humidity is 43-70%, the ventilation is 10-20 times / hour, and the light and dark alternate time of day and night is 12h / 12h; Cobalt 60 radiation sterilized rats were continuously supplied with full-price pellet...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of a probiotic composition in preparation of a medicine for treating tumors. The probiotic comprises Bifidobacterium animalis subsp. Lactis. The medicine also comprises one or more tumor treatment medicines, such as an immune signal path regulator PD-1 / PDL-1 and the like, and the medicines are used for tumor immunotherapy.

Description

technical field [0001] The present disclosure relates to the field of biomedicine, and more specifically, it relates to the use of microorganisms to enhance tumor immunotherapy response. Background technique [0002] Cancer is a malignant disease with a very high mortality rate. It is difficult to treat and has a high mortality rate, which will bring a heavy burden to patients and their families. In recent years, cancer patients around the world have surged. The latest data show that in 2017, there were 24.5 million new cancer cases and 9.6 million cancer deaths worldwide. The top 10 cancers with the highest incidence in the world are: non-melanoma skin cancer (NMSC), TBL (tracheal, bronchus and lung) cancer, breast cancer, colorectal cancer, prostate cancer, gastric cancer, Liver cancer, cervical cancer, non-Hodgkin's lymphoma, and bladder cancer. The top 10 cancers in the global mortality rate are: TBL cancer, colorectal cancer, gastric cancer, liver cancer, breast cance...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/745A61K45/06A61P35/00G16B20/00G16B30/10G16B40/00
CPCA61K35/745A61K45/06A61P35/00G16B20/00G16B30/10G16B40/00A61K2300/00
Inventor 谭验尹意铭刘晓军张凌宇
Owner SHENZHEN JUNTUO BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap